Caspofungin for the treatment of candidaemia in patients with haematological malignancies

Livio Pagano, Brunella Posteraro, Maurizio Sanguinetti, Luana Fianchi, Morena Caira, Giuliana Farina, Giuseppe Leone, R Fanci, A Candoni, M Morselli, Cg Valentini, Me Mitra, M Offidani, Me Tosti, A Nosari, P. Viale

Risultato della ricerca: Contributo in rivistaArticolo in rivista

8 Citazioni (Scopus)

Abstract

This study was prospectively conducted in 11 haematology divisions over a 2-year period to evaluate the efficacy of caspofungin in 24 neutropenic patients with haematological malignancies (HM) and candidaemia. These patients had received chemotherapy for HM and were neutropenic (PNN < 0.5 x 10(9)/L) for a median of 12 days (2-41) before candidaemia. The patients received caspofungin for a median duration of 12 days (range 6-26), obtaining a favourable overall response of 58%. At 30 days, 11 patients had died (46%); candidaemia was responsible for mortality in six patients (25%). These results suggest that treatment of candidaemia with caspofungin in neutropenic HM was efficacious, as it is in non-haematological subgroups.
Lingua originaleEnglish
pagine (da-a)298-301
Numero di pagine4
RivistaClinical Microbiology and Infection
Volume16
DOI
Stato di pubblicazionePubblicato - 2010

Keywords

  • Adult
  • Aged
  • Antifungal Agents
  • Antineoplastic Agents
  • Candidiasis
  • Drug Therapy
  • Echinocandins
  • Female
  • Fungemia
  • Hematologic Neoplasms
  • Humans
  • Male
  • Middle Aged
  • Neutropenia
  • Prospective Studies
  • Treatment Outcome
  • Young Adult

Fingerprint

Entra nei temi di ricerca di 'Caspofungin for the treatment of candidaemia in patients with haematological malignancies'. Insieme formano una fingerprint unica.

Cita questo